Please assess the completion status of the following clinical trial:

Trial Title: Trial of Mifepristone for Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gender: Female~* Age: 18 - premenopausal~* Have at least moderate symptoms of menorrhagia or pelvic pain/pressure~* Have a total uterine volume greater than or equal to 160 cc by ultrasound measurement and at least one fibroid that is =\> 2.5cm in size~* Have a score of equal to or greater than 39 on the Uterine Fibroid Symptom and Quality of Life scale~* Declined standard treatment options for symptomatic fibroids~* Agree to use a double-barrier method (condoms, diaphragms) or other effective non-hormonal methods of contraception (abstinence, sterilization) throughout participation in the study to prevent pregnancy and to report any exposure to pregnancy to the research staff immediately~* Willing and able to give informed consent~* Willing and able to comply with study requirements~Exclusion Criteria:~* Current or planned pregnancy during the study period~* Menopausal, as indicated by follicle stimulating hormone (FSH) level of the reference laboratory~* Currently breast-feeding~* Untreated abnormal pap smear~* Presence of conditions other than fibroids contributing to pain and/or bleeding~* Hemoglobin \< 9.0 mg/dl~* Presence of adnexal masses or tenderness indicating further evaluation or surgery~* Grade III or IV hydronephrosis by ultrasound~* Severe, active mental health disorder~* Active substance abuse or dependence~* Presence of any contraindication to mifepristone including:~  * Adrenal insufficiency by history~ * Sickle cell disease~ * Active liver disease (liver function tests greater than 1.5 times upper range of normal)~ * Severe, respiratory disease (P02 saturation\< 92%)~ * Renal disease (serum creatinine \> 1.5 mg/dl)~ * Blood clotting defect. (abnormal PT and PTT)~ * Thromboembolic disease (history of deep vein thrombosis or pulmonary embolus)~* Current or recent (within the past 3 months) use of the following medications:~  * Oral or systemic corticosteroids~ * Hormones: estrogens, progestins, oral contraceptives~ * Danazol, anticoagulants~* Herbal or botanical supplements with possible hormonal effects.~* Use within the past six months of the gonadotropin releasing hormones (GnRH) analogs or Depo-Provera.~* Current or planned use during the study of any of the following medications/or products:~  * ketoconazole,~ * itraconazole,~ * erythromycin,~ * grapefruit juice,~ * rifampin,~ * St John's Wort,~ * phenytoin,~ * phenobarbital, or~ * carbamazepine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Mifepristone 5 MG capsule taken once daily by mouth
- Inert capsule (Type: PLACEBO_COMPARATOR): Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).